|
- Sutimlimab - Wikipedia
Sutimlimab, sold under the brand name Enjaymo, is a monoclonal antibody that is used to treat adults with cold agglutinin disease (CAD) [1] [3] [4] It is given by intravenous infusion [1] Sutimlimab prevents complement-enhanced activation of autoimmune human B cells in vitro [5]
- Sutimlimab in Cold Agglutinin Disease | New England Journal of Medicine
Sutimlimab (formerly BIVV009) is a first-in-class, humanized monoclonal antibody designed to target C1s, which is responsible for activating the classic complement pathway
- Sutimlimab in patients with cold agglutinin disease: results of the . . .
Sutimlimab, a first-in-class humanized immunoglobulin G4 (IgG4) monoclonal antibody that selectively inhibits the classical complement pathway at C1s, rapidly halted hemolysis in the single-arm CARDINAL study in recently transfused patients with cold agglutinin disease (CAD)
- Sutimlimab Uses, Side Effects Warnings - Drugs. com
What is sutimlimab? Sutimlimab is used to treat the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD) Sutimlimab may also be used for purposes not listed in this medication guide
- Sutimlimab for the Treatment of Cold Agglutinin Disease
Sutimlimab, a humanized monoclonal IgG4 antibody that binds and inactivates complement protein C1s, is the most extensively investigated complement inhibitor for the treatment of CAD This review addresses the preclinical studies of sutimlimab and the studies of pharmacokinetics and pharmacodynamics
- Sutimlimab: First Approval - PubMed
Sutimlimab is an immunoglobulin G, subclass 4 (IgG4) monoclonal antibody that inhibits the classical complement pathway by binding to complement protein component 1, s subcomponent (C1s), a serine protease which cleaves C4 and C2 to form the C3 convertase
- Complement-directed therapy for cold agglutinin disease: sutimlimab
Sutimlimab directly targets classical complement pathway activation and has been shown to be generally well tolerated with rapid and sustained effects on hemoglobin levels, hemolytic markers, and fatigue in patients with CAD
- Long-term sutimlimab improves quality of life for patients with cold . . .
In CARDINAL part B, upstream inhibition of the classical complement pathway in CAD maintained improved patient-reported outcomes at 2 years Sutimlimab provides sustained benefits in chronic CAD, including a continued meaningful impact on patient quality of life
|
|
|